340 related articles for article (PubMed ID: 9872321)
21. Human lung carcinomas express Fas ligand.
Niehans GA; Brunner T; Frizelle SP; Liston JC; Salerno CT; Knapp DJ; Green DR; Kratzke RA
Cancer Res; 1997 Mar; 57(6):1007-12. PubMed ID: 9067260
[TBL] [Abstract][Full Text] [Related]
22. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
23. The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway.
Liu B; Fan Z
Oncogene; 2001 Jun; 20(28):3726-34. PubMed ID: 11439335
[TBL] [Abstract][Full Text] [Related]
24. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells.
Kashii Y; Giorda R; Herberman RB; Whiteside TL; Vujanovic NL
J Immunol; 1999 Nov; 163(10):5358-66. PubMed ID: 10553060
[TBL] [Abstract][Full Text] [Related]
25. Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis.
Martin JH; Potthoff A; Ledig S; Cornberg M; Jandl O; Manns MP; Kubicka S; Flemming P; Athmann C; Beil W; Wagner S
Helicobacter; 2004 Oct; 9(5):371-86. PubMed ID: 15361075
[TBL] [Abstract][Full Text] [Related]
26. Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells.
Zhu Q; Liu JY; Yang CM; Xu HW; Zhang AZ; Cui Y; Wang HB; Qin CY; Li YQ
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1071-7. PubMed ID: 16957513
[TBL] [Abstract][Full Text] [Related]
27. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Kim R; Emi M; Tanabe K; Uchida Y; Toge T
Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
[TBL] [Abstract][Full Text] [Related]
28. Fas ligand induction in human NK cells is regulated by redox through a calcineurin-nuclear factors of activated T cell-dependent pathway.
Furuke K; Shiraishi M; Mostowski HS; Bloom ET
J Immunol; 1999 Feb; 162(4):1988-93. PubMed ID: 9973469
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia.
Kim S; Fotiadu A; Kotoula V
Clin Immunol; 2005 Jun; 115(3):286-94. PubMed ID: 15893696
[TBL] [Abstract][Full Text] [Related]
30. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance.
Connor JP; Felder M
Gynecol Oncol; 2008 Nov; 111(2):330-5. PubMed ID: 18723214
[TBL] [Abstract][Full Text] [Related]
31. Human colon cancer cells express the functional Fas ligand.
Ding EX; Hizuta A; Morimoto Y; Tanida T; Hongo T; Ishii T; Yamano T; Fujiwara T; Iwagaki H; Tanaka N
Res Commun Mol Pathol Pharmacol; 1998 Jul; 101(1):13-24. PubMed ID: 9755840
[TBL] [Abstract][Full Text] [Related]
32. Tumor necrosis factor-alpha and interferon-gamma induce expression of functional Fas ligand on HT29 and MCF7 adenocarcinoma cells.
Naujokat C; Sezer O; Possinger K
Biochem Biophys Res Commun; 1999 Nov; 264(3):813-9. PubMed ID: 10544014
[TBL] [Abstract][Full Text] [Related]
33. Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: modulation by cytokines.
Arnold R; Seifert M; Asadullah K; Volk HD
J Immunol; 1999 Jun; 162(12):7140-7. PubMed ID: 10358159
[TBL] [Abstract][Full Text] [Related]
34. Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells.
Petak I; Tillman DM; Harwood FG; Mihalik R; Houghton JA
Cancer Res; 2000 May; 60(10):2643-50. PubMed ID: 10825136
[TBL] [Abstract][Full Text] [Related]
35. Human Fas-ligand expression on porcine endothelial cells does not protect against xenogeneic natural killer cytotoxicity.
Matter-Reissmann UB; Sonntag KC; Gilli UO; Leguern C; Schneider MK; Seebach JD
Xenotransplantation; 2004 Jan; 11(1):43-52. PubMed ID: 14962292
[TBL] [Abstract][Full Text] [Related]
36. Human dendritic cells mediate anti-tumor activity against hematopoietic tumor cells without direct contact and Fas/FasL killing pathway.
Ayres FM; Narita M; Takahashi M; Yano T; Liu A; Toba K; Furukawa T; Aizawa Y
Oncol Rep; 2004 May; 11(5):1017-23. PubMed ID: 15069541
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
[TBL] [Abstract][Full Text] [Related]
38. Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells.
Kim KM; Lee K; Hong YS; Park HY
Exp Mol Med; 2000 Dec; 32(4):246-54. PubMed ID: 11190279
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the ligand binding site in Fas (CD95) by site-directed mutagenesis and comparison with TNFR and CD40.
Starling GC; Kiener PA; Aruffo A; Bajorath J
Biochemistry; 1998 Mar; 37(11):3723-6. PubMed ID: 9521690
[TBL] [Abstract][Full Text] [Related]
40. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT.
Wroblewski VJ; Witcher DR; Becker GW; Davis KA; Dou S; Micanovic R; Newton CM; Noblitt TW; Richardson JM; Song HY; Hale JE
Biochem Pharmacol; 2003 Feb; 65(4):657-67. PubMed ID: 12566095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
